AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35028764 — intervention group
Group type: COMPARATOR
Intervention: DSG/EE group
Number of subjects: 156
Study 35028764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 156
Study 34457024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 31
Study 34457024 — intervention group
Group type: COMPARATOR
Intervention: Control (no hypnosis)
Number of subjects: 31
Study 34457024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Hypnosis and Control)
Number of subjects: 31
Study 35413919 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE
Number of subjects: 344
Study 35413919 — intervention group
Group type: COMPARATOR
Intervention: Adapted PACE
Number of subjects: 344
Study 33355814 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection at lateral sites of internal sphincter muscle (group 1)
Number of subjects: 80
Study 33355814 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection at anterior and posterior regions (group 2)
Number of subjects: 80
Study 36279134 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based primary prophylactic colony-stimulating factor standing order system
Number of subjects: 2946
Study 36279134 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2946
Study 33625621 — intervention group
Group type: EXPERIMENTAL
Intervention: SWITCH TO TMP‐SMX group
Number of subjects: 70
Study 33625621 — intervention group
Group type: COMPARATOR
Intervention: NO SWITCH TO TMP‐SMX group
Number of subjects: 70
Study 35786077 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning and RehaGoal App‐based dressing practice (seven sessions of 45 min)
Number of subjects: 24
Study 35786077 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy in the rehab unit
Number of subjects: 24
Study 35786077 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning and RehaGoal App‐based dressing practice
Number of subjects: 24
Study 33539228 — intervention group
Group type: EXPERIMENTAL
Intervention: Laptop note-taking
Number of subjects: 142
Study 33539228 — intervention group
Group type: COMPARATOR
Intervention: Longhand note-taking
Number of subjects: 142
Study 33539228 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher word count
Number of subjects: 142
Study 33539228 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher verbatim overlap
Number of subjects: 142
Study 32282739 — intervention group
Group type: COMPARATOR
Intervention: Control group: undiluted contrast agent (2 ml/kg, upper limit 50 ml) injected 1 time.
Number of subjects: 100
Study 32282739 — intervention group
Group type: EXPERIMENTAL
Intervention: Research group: first bolus of 20% diluted contrast agent (1 ml/kg, upper limit 25 ml) followed by undiluted contrast agent (1 ml/kg, upper limit 25 ml).
Number of subjects: 100
Study 34633508 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm environmental temperature (31 °C)
Number of subjects: 20
Study 34633508 — intervention group
Group type: COMPARATOR
Intervention: Control environmental temperature (21 °C)
Number of subjects: 20
Study 34633508 — intervention group
Group type: EXPERIMENTAL
Intervention: AS group
Number of subjects: 20
Study 34633508 — intervention group
Group type: COMPARATOR
Intervention: AA group
Number of subjects: 20
Study 33784280 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oral feeding (8 hours after management)
Number of subjects: 59
Study 33784280 — intervention group
Group type: COMPARATOR
Intervention: Early oral feeding (48 hours after management)
Number of subjects: 59
Study 35095912 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with 500 mg/kg of Gallic Acid + transportation (TS+GA)
Number of subjects: 19
Study 35095912 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + transportation (TS)
Number of subjects: 19
Study 32007694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (40 mg/d for 12 weeks)
Number of subjects: 80
Study 32007694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34269807 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (enhanced barrier precautions, chlorhexidine bathing, MDRO surveillance, environmental cleaning education and feedback, hand hygiene promotion, health care worker education and feedback)
Number of subjects: 245
Study 34269807 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care practices)
Number of subjects: 245
Study 34269807 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 245
Study 36388236 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (PTNS)
Number of subjects: 16
Study 36388236 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 16
Study 32001614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic management
Number of subjects: 1441
Study 32001614 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal glycemic control after a first event
Number of subjects: 1441
Study 32001614 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c (per 1% higher)
Number of subjects: 1441
Study 32001614 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c (for subsequent events)
Number of subjects: 1441
Study 34478173 — intervention group
Group type: EXPERIMENTAL
Intervention: NGT-G
Number of subjects: 223
Study 34478173 — intervention group
Group type: COMPARATOR
Intervention: LT
Number of subjects: 223
Study 34152828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg once daily (with a possible dose increase to 400 mg)
Number of subjects: 1222
Study 34152828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study 32634571 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD in powder form
Number of subjects: 12
Study 32634571 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD in sesame oil
Number of subjects: 12
Study 32634571 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD in self-nano-emulsifying drug delivery system (SNEDDS)
Number of subjects: 12
Study 32634571 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based vehicles (sesame oil and SNEDDS)
Number of subjects: 12
Study 35267110 — intervention group
Group type: EXPERIMENTAL
Intervention: SWEEPS
Number of subjects: 200
Study 35267110 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPS
Number of subjects: 200
Study 35267110 — intervention group
Group type: COMPARATOR
Intervention: PUI
Number of subjects: 200
Study 35267110 — intervention group
Group type: COMPARATOR
Intervention: sonic (EDDY)
Number of subjects: 200
Study 35267110 — intervention group
Group type: COMPARATOR
Intervention: MDA
Number of subjects: 200
Study 33990435 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed cervical interlaminar epidural steroid injection with triamcinolone
Number of subjects: 117
Study 33990435 — intervention group
Group type: COMPARATOR
Intervention: Cervical transforaminal steroid injection with dexamethasone
Number of subjects: 117
Study 32799709 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 517
Study 32799709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study 32799709 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HII ≤0.5
Number of subjects: 517
Study 35276993 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept IF with large, milk phospholipid-coated lipid droplets and prebiotic mixture (scGOS/lcFOS 9:1)
Number of subjects: 92
Study 35276993 — intervention group
Group type: COMPARATOR
Intervention: Control IF with prebiotics
Number of subjects: 92
Study 35276993 — intervention group
Group type: COMPARATOR
Intervention: Control IF without prebiotics
Number of subjects: 92
Study 34607784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using Ga Al As laser with a wavelength of 810nm and a power of 100 mW, applied on days 0, 3, 30, and 60 for 18 seconds each time.
Number of subjects: 60
Study 34607784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral LED device with a wavelength of 640nm and a power density of 40 mW/cm2, used 5 minutes per day.
Number of subjects: 60
Study 34607784 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment using a coated light cure device, following the same protocol as the laser group.
Number of subjects: 60
Study 36429935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training program (postural control and fine motor skills exercises)
Number of subjects: 0
Study 36429935 — intervention group
Group type: COMPARATOR
Intervention: Stretching program (Control group)
Number of subjects: 0
Study 33844996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 µg per actuation, 2 inhalations twice a day until symptom resolution)
Number of subjects: 146
Study 33844996 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 146
Study 34378493 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged high-loading intervention for 3 months using a mobile set-up
Number of subjects: 12
Study 34378493 — intervention group
Group type: COMPARATOR
Intervention: Control leg (contralateral/untrained leg)
Number of subjects: 12
Study 32432684 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 5711
Study 32432684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5711
Study 32003649 — intervention group
Group type: EXPERIMENTAL
Intervention: modified alternate‐day fasting diet
Number of subjects: 80
Study 36038833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (quarterly)
Number of subjects: 1500
Study 36038833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (monthly)
Number of subjects: 1500
Study 36038833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 36038833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (quarterly and monthly)
Number of subjects: 1500
Study 34578959 — intervention group
Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention
Number of subjects: 468
Study 32473275 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 49
Study 32473275 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 49
Study 32473275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 36224641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 5:2
Number of subjects: 50
Study 36224641 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 34668352 — intervention group
Group type: EXPERIMENTAL
Intervention: No-Touch Radiofrequency Ablation (NT-RFA)
Number of subjects: 73
Study 34668352 — intervention group
Group type: COMPARATOR
Intervention: Conventional Radiofrequency Ablation (RFA)
Number of subjects: 73
Study 34668352 — intervention group
Group type: COMPARATOR
Intervention: RFA type (NT-RFA vs Conventional RFA)
Number of subjects: 73
Study 35727800 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Assessment Protocol (GAP)
Number of subjects: 24096
Study 35727800 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24096
Study 35727800 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP
Number of subjects: 24096
Study 32654098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, chloroquine, or azithromycin
Number of subjects: 105
Study 32654098 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc > 500 ms or an increase of 60 ms
Number of subjects: 105
Study 35286860 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled 7% hypertonic saline
Number of subjects: 116
Study 35286860 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline
Number of subjects: 116
Study 35286860 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hypertonic saline vs isotonic saline
Number of subjects: 116
Study 33734828 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atomoxetine + 5 mg solifenacin succinate (ato-sol)
Number of subjects: 10
Study 33734828 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atomoxetine + 2 mg biperiden hydrochloride (ato-bip)
Number of subjects: 10
Study 33734828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 35781439 — intervention group
Group type: EXPERIMENTAL
Intervention: Qmix
Number of subjects: 90
Study 35781439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan
Number of subjects: 90
Study 35781439 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA/sodium hypochlorite
Number of subjects: 90
Study 35781439 — intervention group
Group type: COMPARATOR
Intervention: Irradiated group
Number of subjects: 90
Study 35781439 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated group
Number of subjects: 90
Study 34006565 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (up to 2,000 mg)
Number of subjects: 121
Study 34006565 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss
Number of subjects: 121
Study 34006565 — intervention group
Group type: COMPARATOR
Intervention: Self-directed care (control)
Number of subjects: 121
Study 32532790 — intervention group
Group type: EXPERIMENTAL
Intervention: BR induction followed by 2-year rituximab maintenance (BR-R)
Number of subjects: 289
Study 32532790 — intervention group
Group type: EXPERIMENTAL
Intervention: BR with bortezomib and rituximab maintenance (BVR-R)
Number of subjects: 289
Study 32532790 — intervention group
Group type: EXPERIMENTAL
Intervention: BR followed by lenalidomide (1 year) with rituximab maintenance (BR-LR)
Number of subjects: 289
Study 32532790 — intervention group
Group type: COMPARATOR
Intervention: BR-R
Number of subjects: 289
Study 32532790 — intervention group
Group type: COMPARATOR
Intervention: BVR-R
Number of subjects: 289
Study 32532790 — intervention group
Group type: COMPARATOR
Intervention: BR-LR
Number of subjects: 289
Study 35301854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Number of subjects: 53
Study 36403205 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop automated oxygen control (CLAC)
Number of subjects: 16
Study 36403205 — intervention group
Group type: COMPARATOR
Intervention: Standard care (manual oxygen control)
Number of subjects: 16
Study 34210154 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased TSH
Number of subjects: 134641
Study 34210154 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased fT4
Number of subjects: 134641
Study 34210154 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted hyperthyroidism
Number of subjects: 134641
Study 34210154 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted hypothyroidism
Number of subjects: 134641
Study 35651299 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate injection
Number of subjects: 100
Study 35651299 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 100
Study 34351436 — intervention group
Group type: EXPERIMENTAL
Intervention: GX301 cancer vaccine regimen 1 (eight administrations)
Number of subjects: 98
Study 34351436 — intervention group
Group type: EXPERIMENTAL
Intervention: GX301 cancer vaccine regimen 2 (four administrations)
Number of subjects: 98
Study 34351436 — intervention group
Group type: COMPARATOR
Intervention: GX301 cancer vaccine regimen 3 (two administrations)
Number of subjects: 98
Study 34351436 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival across all regimens
Number of subjects: 98
Study 36173326 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating bilateral training
Number of subjects: 24
Study 36173326 — intervention group
Group type: COMPARATOR
Intervention: Unilateral training
Number of subjects: 24
Study 36173326 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating bilateral training (specifically for left hemiparesis)
Number of subjects: 24
Study 36173326 — intervention group
Group type: COMPARATOR
Intervention: Unilateral training (specifically for left hemiparesis)
Number of subjects: 24
Study 34241801 — intervention group
Group type: EXPERIMENTAL
Intervention: Buxue Yimu Pills (BYP, 24 g/d)
Number of subjects: 150
Study 34241801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FS Tablets, 0.9 g/d)
Number of subjects: 150
Study 34241801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BYP and FS (BYP 24 g/d plus FS Tablets 0.9 g/d)
Number of subjects: 150
Study 34241801 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 32711435 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement program
Number of subjects: 130
Study 32711435 — intervention group
Group type: COMPARATOR
Intervention: Knowledge and usual care by health personnel
Number of subjects: 130
Study 34933917 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention guided by a cognitive map (the 'empathy circle') with motivational texts.
Number of subjects: 221
Study 34933917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 221
Study 33847977 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 216
Study 33847977 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 216
Study 32682494 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir (300 mg and 120 mg, three tablets daily for 8 weeks)
Number of subjects: 546
Study 32682494 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir (300 mg and 120 mg, three tablets daily for 12 weeks)
Number of subjects: 546
Study 32682494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 32682494 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir
Number of subjects: 546
Study 36353338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training + dill supplementation (PDG)
Number of subjects: 45
Study 36353338 — intervention group
Group type: COMPARATOR
Intervention: Pilates training + placebo (PPG)
Number of subjects: 45
Study 36353338 — intervention group
Group type: COMPARATOR
Intervention: Dill supplementation (DG)
Number of subjects: 45
Study 36353338 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 45
Study 34488847 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy (two sessions between 14 and 35 days postpartum)
Number of subjects: 0
Study 34488847 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 0
Study 34488847 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 0
Study 33186304 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 138
Study 33186304 — intervention group
Group type: EXPERIMENTAL
Intervention: Video games (tablet with videogame applications)
Number of subjects: 138
Study 33186304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon ('Şüko Is Being Operated')
Number of subjects: 138
Study 33186304 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 138
Study 35500465 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 0.45 mg/kg/d
Number of subjects: 97
Study 35500465 — intervention group
Group type: COMPARATOR
Intervention: Deflazacort 0.9 mg/kg/d
Number of subjects: 97
Study 33833945 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine technology-based program with comprehensive counseling and biweekly remote support for 3 months
Number of subjects: 100
Study 33833945 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving routine care with individual single-session counseling
Number of subjects: 100
Study 34293934 — intervention group
Group type: EXPERIMENTAL
Intervention: RISE intervention (8-week psychoeducational group program)
Number of subjects: 75
Study 34293934 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 75
Study 33999753 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsvall needle prototype
Number of subjects: 10
Study 33999753 — intervention group
Group type: COMPARATOR
Intervention: Standard Tru-Cut needle (BARD 18 G)
Number of subjects: 10
Study 32794483 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and internal fixation with dynamic hip screw (Group A)
Number of subjects: 90
Study 32794483 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and internal fixation by proximal femoral nail (Group B)
Number of subjects: 90
Study 33034748 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics score combined with ACR guidelines (Rad_5%)
Number of subjects: 1609
Study 33034748 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics score combined with ATA guidelines (Rad_5%)
Number of subjects: 1609
Study 33034748 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics score alone
Number of subjects: 1609
Study 32716700 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-approved vaccines with postapproval safety-related label modifications
Number of subjects: 57
Study 32716700 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved vaccines without postapproval safety-related label modifications
Number of subjects: 57
Study 32716700 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmarketing surveillance data
Number of subjects: 57
Study 32716700 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety issues identified through postmarketing surveillance
Number of subjects: 57
Study 33967252 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.00 D add multifocal lenses
Number of subjects: 11
Study 33967252 — intervention group
Group type: EXPERIMENTAL
Intervention: +3.00 D add multifocal lenses
Number of subjects: 11
Study 33967252 — intervention group
Group type: EXPERIMENTAL
Intervention: +4.00 D add multifocal lenses
Number of subjects: 11
Study 33967252 — intervention group
Group type: COMPARATOR
Intervention: Single-vision lenses
Number of subjects: 11
Study 33427173 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher caregiving quality at age 12
Number of subjects: 0
Study 33427173 — intervention group
Group type: EXPERIMENTAL
Intervention: Never-institutionalized children
Number of subjects: 0
Study 33427173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-institutionalized children
Number of subjects: 0
Study 33427173 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care placement
Number of subjects: 0